lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer (LC) is a leading cause of cancer-related mortality.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
• NORAD (non-coding RNA activated by DNA damage) is implicated in various human cancers.

Purpose of the Study:

• To investigate the mechanism of lncRNA NORAD in the progression of lung cancer.
• To determine the regulatory role of NORAD in LC cell proliferation, invasion, and migration.
• To elucidate the molecular interactions involving NORAD, miR-28-3p, and E2F2 in lung cancer.

Main Methods:

• Quantitative real-time PCR to assess NORAD expression in normal and LC cells.
• RNA interference (si-NORAD) to silence NORAD and evaluate its effects on LC cell behavior.
• Bioinformatic analysis and RNA fractionation assays for subcellular localization of NORAD.
• Luciferase reporter assays and western blotting to verify targeting relationships between NORAD, miR-28-3p, and E2F2.
• Rescue experiments involving transfection with miR-28-3p inhibitors or E2F2 expression vectors.

Main Results:

• NORAD was significantly overexpressed in lung cancer cells compared to normal lung cells.
• Silencing NORAD expression suppressed proliferation, invasion, and migration of LC cells.
• NORAD was found to function as a competing endogenous RNA (ceRNA), sponging miR-28-3p.
• miR-28-3p was confirmed to directly target and inhibit E2F2 expression.
• Inhibition of miR-28-3p or overexpression of E2F2 could reverse the suppressive effects of NORAD silencing on LC cell progression.

Conclusions:

• NORAD acts as a crucial oncogenic lncRNA in lung cancer progression.
• The NORAD/miR-28-3p/E2F2 axis plays a significant role in regulating LC cell proliferation, invasion, and migration.
• NORAD promotes lung cancer progression by competitively binding to miR-28-3p, thereby upregulating E2F2.